338966-53-3

Upstream product

• 338417-50-8 methyl 3-(2-chloro-6-fluorophenyl)-5-(2-(dimethylamino)vinyl)isoxazole-4-carboxylate 
• 407-25-0 trifluoroacetic anhydride 
• 4415-09-2 methyl 3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylate 

Downstream Products

• 1391943-24-0 methyl 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole-4-carboxylate 
• 1391944-13-0 methyl 3-(2-chloro-6-fluorophenyl)-5-{[1-(4-methoxycarbonyl-3-(4-chlorophenyl)isoxazol-5-yl)-5-trifluoromethyl-1H-pyrazol-4-yl]}-isoxazole-4-carboxylate 
• 1391943-30-8 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-N-methoxy-N-methylisoxazole-4-carboxamide 
• 1391943-36-4 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole-4-carboxamide 
• 1391943-37-5 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole-4-carboxylic acid 
• 1391943-38-6 (3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazol-4-yl)(morpholino)methanone 
• 1391943-51-3 S-methyl 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole-4-carbothioate 
• 1391944-16-3 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-4-(thiazol-2-yl)isoxazole 
• 1391944-18-5 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole-4-carbothioamide 
• 1391944-22-1 methyl 3-(2-chloro-6-fluorophenyl)-5-(1-(2,4-difluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole-4-carboxylate 
• 1391944-26-5 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-4-(oxazol-5-yl)isoxazole 
• 1391944-29-8 C₂₀H₉Cl₂F₄N₃O₂ 

Relevant academic research and scientific papers

IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.

IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.